PTC Therapeutics Shiller PE Ratio

: (As of Today)

View and export this data going back to 2013. Start your Free Trial

Shiller PE for Stocks: The True Measure of Stock Valuation

PTC Therapeutics Shiller PE Ratio Historical Data

The historical data trend for PTC Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PTC Therapeutics Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Shiller PE Ratio

PTC Therapeutics Quarterly Data
	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22
Shiller PE Ratio																-	-	-	-	-

Competitive Comparison

For the Biotechnology subindustry, PTC Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Annual Data Quarterly Data

PTC Therapeutics Shiller PE Ratio Distribution

For the Biotechnology industry and Healthcare sector, PTC Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where PTC Therapeutics's Shiller PE Ratio falls into.

PTC Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

PTC Therapeutics's E10 for the quarter that ended in Mar. 2022 is calculated as:

For example, PTC Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2022 was:

Adj_EPS	=	Earnings per Share (Diluted)	/	CPI of Mar. 2022 (Change)	*	Current CPI (Mar. 2022)
	=	-1.78	/	121.3010	*	121.3010
	=	-1.780

Current CPI (Mar. 2022) = 121.3010.

PTC Therapeutics Quarterly Data

	Earnings per Share (Diluted)	CPI	Adj_EPS
201206	0.022	96.819	0.028
201209	-0.514	97.633	-0.639
201212	0.008	96.871	0.010
201303	-1.248	98.209	-1.541
201306	-5.510	98.518	-6.784
201309	-0.190	98.790	-0.233
201312	-0.751	98.326	-0.926
201403	-0.580	99.695	-0.706
201406	-0.860	100.560	-1.037
201409	-0.930	100.428	-1.123
201412	-0.840	99.070	-1.028
201503	-1.150	99.621	-1.400
201506	-1.140	100.684	-1.373
201509	-1.270	100.392	-1.535
201512	-1.500	99.792	-1.823
201603	-1.220	100.470	-1.473
201606	-1.140	101.688	-1.360
201609	-1.030	101.861	-1.227
201612	-0.780	101.863	-0.929
201703	-0.850	102.862	-1.002
201706	-0.440	103.349	-0.516
201709	-0.820	104.136	-0.955
201712	0.030	104.011	0.035
201803	-0.460	105.290	-0.530
201806	-0.210	106.317	-0.240
201809	-1.060	106.507	-1.207
201812	-0.960	105.998	-1.099
201903	-1.290	107.251	-1.459
201906	-0.750	108.070	-0.842
201909	-1.060	108.329	-1.187
201912	-1.370	108.420	-1.533
202003	-1.810	108.902	-2.016
202006	-2.780	108.767	-3.100
202009	-1.030	109.815	-1.138
202012	-1.050	109.897	-1.159
202103	-1.830	111.754	-1.986
202106	-1.680	114.631	-1.778
202109	-1.890	115.734	-1.981
202112	-2.030	117.630	-2.093
202203	-1.780	121.301	-1.780

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

PTC Therapeutics (NAS:PTCT) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.

Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.

PTC Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of PTC Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

PTC Therapeutics Business Description

Industry

Healthcare » Biotechnology NAICS : 325412 SIC : 2834

Comparable Companies

ROCO:6550 OTCPK:VSBC NAS:HRMY NAS:VIR NAS:BEAM NAS:CVAC NAS:RLAY SHSE:688520 BOM:539268 SHSE:603229

Traded in Other Exchanges

P91:Germany P91:Germany

Address

100 Corporate Court, South Plainfield, NJ, USA, 07080

Website

https://www.ptcbio.com

PTC Therapeutics Inc is a global biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule therapeutics. Its target area is RNA biology post-transcriptional control processes of the events occurring in a cell when a RNA messenger is copied from DNA during the transcription process. The discovered products address multiple therapeutic areas, including rare disorders, such as nonsense mutations in Duchenne muscular dystrophy and oncology.

Executives

Southwell David P	director	C/O INOTEK PHARMACEUTICALS CORPORATION 91 HARTWELL AVENUE LEXINGTON MA 02421
Jacobson Allan Steven	director	PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080
Peltz Stuart Walter	director, officer: Chief Executive Officer	PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080
Utter Christine Marie	officer: SVP, Finance & CAO	C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080
Boulding Mark Elliott	officer: Exec. VP and CLO	C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080
Hill Emily Luisa	officer: Chief Financial Officer	C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080
Svoronos Dawn	director	C/O MEDIVATION, INC. 525 MARKET ST., 36TH FLOOR SAN FRANCISCO CA 94105
Pauwels Eric	officer: Chief Business Officer	550 HILLS DRIVE BEDMINSTER NJ 07921
Klein Matthew B.	officer: Chief Development Officer	C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080
Schmertzler Michael	director	1300 VALLEY ROAD NEW CANAAN CT 06840
Souza Marcio	officer: Chief Operating Officer	C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080
Almstead Neil Gregory	officer: Chief Technical Ops Officer	C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080
Reeve Emma	director	C/O PAREXEL INTERNATIONAL CORPORATION 195 WEST STREET WALTHAM MA 02451
Steele Glenn Jr Md Phd	director	250 TECHNOLOGY PARK LAKE MARY FL 32746-6232
Zeldis Jerome B	director	8767 E. VIA DE VENTURA, SUITE 190 SCOTTSDALE AZ 85258

PTC Therapeutics Headlines

From GuruFocus

PTC Therapeutics Announces Launch of 8th Annual STRIVE� Awards Program to Fund Initiatives Benefitting the Duchenne Muscular Dystrophy Community

By PRNewswire 01-18-2022

Oral Splicing Modifiers that Systemically Lower Huntington Disease Protein Discovered Through PTC Therapeutics' Innovative Splicing Platform

By PRNewswire 12-20-2021